(Q37766374)

22 August 2017

1 reference

title

Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab (English)

1 reference

22 August 2017

1 reference

1 reference

1 reference

1 reference

head and neck carcinoma

1 reference

Chulso Moon

1

1 reference

22 August 2017

Young Kwang Chae

series ordinal

2

1 reference

22 August 2017

Juna Lee

series ordinal

3

1 reference

22 August 2017

publication date

18 June 2010

1 reference

Experimental Biology and Medicine

22 August 2017

published in

1 reference

22 August 2017

volume

235

1 reference

22 August 2017

issue

8

1 reference

22 August 2017

page(s)

907-920

1 reference

Treatment of locally advanced head and neck cancer: historical and critical review

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Molecular pathogenesis of head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Mechanisms of cutaneous toxicities to EGFR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Panitumumab a novel drug in cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Targeted therapies in head and neck cancer: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

In vivo expansion of gene-modified hematopoietic cells by a novel selective amplifier gene utilizing the erythropoietin receptor as a molecular switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

Prognostic Value of an Activation State Marker for Epidermal Growth Factor Receptor in Tissue Microarrays of Head and Neck Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2009.009181

21 January 2018

Identifiers

DOI

10.1258/EBM.2009.009181

1 reference

22 August 2017

1 reference